|
1
|
Robbins AS, Siegel RL and Jemal A: Racial
disparities in stage-specific colorectal cancer mortality rates
from 1985 to 2008. J Clin Oncol. 30:401–405. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bultman SJ: Interplay between diet, gut
microbiota, epigenetic events, and colorectal cancer. Mol Nutr Food
Res. May 3–2016.(Epub ahead of print). doi: 10.1002/mnfr.201500902.
PubMed/NCBI
|
|
3
|
Itatani Y, Kawada K, Inamoto S, Yamamoto
T, Ogawa R, Taketo MM and Sakai Y: The role of chemokines in
promoting colorectal cancer invasion/metastasis. Int J Mol Sci.
17:pii: E643. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Meads MB, Gatenby RA and Dalton WS:
Environment-mediated drug resistance: A major contributor to
minimal residual disease. Nat Rev Cancer. 9:665–674. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kraus WL: Transcriptional control by
PARP-1: Chromatin modulation, enhancer-binding, coregulation, and
insulation. Curr Opin Cell Biol. 20:294–302. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Clayton C and Hotz HR:
Post-transcriptional control of PARP gene expression. Mol Biochem
Parasitol. 77:1–6. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hassa PO and Hottiger MO: The diverse
biological roles of mammalian PARPS, a small but powerful family of
poly-ADP-ribose polymerases. Front Biosci. 13:3046–3082. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hakmé A, Wong HK, Dantzer F and Schreiber
V: The expanding field of poly(ADP-ribosyl)ation reactions.
‘Protein Modifications: Beyond the Usual Suspects’ Review Series.
EMBO Rep. 9:1094–1100. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Honda S, Minato M, Suzuki H, Fujiyoshi M,
Miyagi H, Haruta M, Kaneko Y, Hatanaka KC, Hiyama E, Kamijo T, et
al: Clinical prognostic value of DNA methylation in hepatoblastoma:
Four novel tumor suppressor candidates. Cancer Sci. 107:812–819.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gonçalves A, Sabatier R, Charafe-Jauffret
E, Gilabert M, Provansal M, Tarpin C, Extra JM, Viens P and
Bertucci F: Triple-negative breast cancer: Histoclinical and
molecular features, therapeutic management and perspectives. Bull
Cancer. 100:453–464. 2013.(In French). PubMed/NCBI
|
|
11
|
Porcelli L, Quatrale AE, Mantuano P, Leo
MG, Silvestris N, Rolland JF, Carioggia E, Lioce M, Paradiso A and
Azzariti A: Optimize radiochemotherapy in pancreatic cancer: PARP
inhibitors a new therapeutic opportunity. Mol Oncol. 7:308–322.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Salemi M, Galia A, Fraggetta F, La Corte
C, Pepe P, La Vignera S, Improta G, Bosco P and Calogero AE: Poly
(ADP-ribose) polymerase 1 protein expression in normal and
neoplastic prostatic tissue. Eur J Histochem. 57:e132013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Qi G, Kudo Y, Tang B, Liu T, Jin S, Liu J,
Zuo X, Mi S, Shao W, Ma X, et al: PARP6 acts as a tumor suppressor
via downregulating Survivin expression in colorectal cancer.
Oncotarget. 7:18812–18824. 2016.PubMed/NCBI
|
|
14
|
Tuncel H, Tanaka S, Oka S, Nakai S,
Fukutomi R, Okamoto M, Ota T, Kaneko H, Tatsuka M and Shimamoto F:
PARP6, a mono(ADP-ribosyl) transferase and a negative regulator of
cell proliferation, is involved in colorectal cancer development.
Int J Oncol. 41:2079–2086. 2012.PubMed/NCBI
|
|
15
|
Fragni M, Bonini SA, Stabile A, Bodei S,
Cristinelli L, Simeone C, Zani D, Spano PF, Berruti A, Memo M, et
al: Inhibition of survivin is associated with zoledronic
acid-induced apoptosis of prostate cancer cells. Anticancer Res.
36:913–920. 2016.PubMed/NCBI
|
|
16
|
Wu J, Zhao S, Zhang J, Qu X, Jiang S,
Zhong Z, Zhang F, Wong Y and Chen H: Over-expression of survivin is
a factor responsible for differential responses of ovarian cancer
cells to S-allylmercaptocysteine (SAMC). Exp Mol Pathol.
100:294–302. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang W, Mao Y, Zhan Y, Huang J, Wang X,
Luo P, Li LI, Mo D, Liu Q, Xu H, et al: Prognostic implications of
survivin and lung resistance protein in advanced non-small cell
lung cancer treated with platinum-based chemotherapy. Oncol Lett.
11:723–730. 2016.PubMed/NCBI
|
|
18
|
Ma WH, Liu YC, Xue ML, Zheng Z and Ge YL:
Downregulation of survivin expression exerts antitumoral effects on
mouse breast cancer cells in vitro and in vivo. Oncol
Lett. 11:159–167. 2016.PubMed/NCBI
|
|
19
|
Zhu J, Sun C, Wang L, Xu M, Zang Y, Zhou
Y, Liu X, Tao W, Xue B, Shan Y, et al: Targeting survivin using a
combination of miR 494 and survivin shRNA has synergistic effects
on the suppression of prostate cancer growth. Mol Med Rep.
13:1602–1610. 2016.PubMed/NCBI
|
|
20
|
Wang H, Yang M, Xu J, Zou B, Zhou Q, Bian
J and Wang X: Survivin mRNA-circulating tumor cells are associated
with prostate cancer metastasis. Tumour Biol. 37:723–727. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang B, Huang J, Liu H, Guo W and Li G:
miR-335 directly, while miR-34a indirectly modulate survivin
expression and regulate growth, apoptosis, and invasion of gastric
cancer cells. Tumour Biol. 37:1771–1779. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang TA, Zhang XD, Guo XY, Xian SL and Lu
YF: 3-Bromopyruvate and sodium citrate target glycolysis, suppress
survivin, and induce mitochondrial-mediated apoptosis in gastric
cancer cells and inhibit gastric orthotopic transplantation tumor
growth. Oncol Rep. 35:1287–1296. 2016.PubMed/NCBI
|
|
23
|
Zhang B, Leng C, Wu C, Zhang Z, Dou L, Luo
X, Zhang B and Chen X: Smad4 sensitizes colorectal cancer to
5-fluorouracil through cell cycle arrest by inhibiting the
PI3K/Akt/CDC2/survivin cascade. Oncol Rep. 35:1807–1815.
2016.PubMed/NCBI
|
|
24
|
Li WL, Lee MR and Cho MY: The small
molecule survivin inhibitor YM155 may be an effective treatment
modality for colon cancer through increasing apoptosis. Biochem
Biophys Res Commun. 471:309–314. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Steponaitis G, Skiriutė D, Kazlauskas A,
Golubickaitė I, Stakaitis R, Tamašauskas A and Vaitkienė P: High
CHI3L1 expression is associated with glioma patient
survival. Diagn Pathol. 11:422016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Qu Y, Gu C, Wang H, Chang K, Yang X, Zhou
X, Dai B, Zhu Y, Shi G, Zhang H, et al: Diagnosis of adults Xp11.2
translocation renal cell carcinoma by immunohistochemistry and FISH
assays: Clinicopathological data from ethnic Chinese population.
Sci Rep. 6:216772016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee WK and Kang JS: Modulation of
apoptosis and differentiation by the treatment of sulfasalazine in
rabbit articular chondrocytes. Toxicol Res. 32:115–121. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Schreiber V, Dantzer F, Ame JC and de
Murcia G: Poly(ADP-ribose): Novel functions for an old molecule.
Nat Rev Mol Cell Biol. 7:517–528. 2006. View Article : Google Scholar : PubMed/NCBI
|
